Evidence map›Paper›PMID 33913706›Full record

ArticleBiochemistry2021

A Complete Survey of RhoGDI Targets Reveals Novel Interactions with Atypical Small GTPases.

Ana Masara Binti Ahmad Mokhtar, Samrein B M Ahmed, Nicola J Darling, Matthew Harris, Helen R Mott, Darerca Owen

Open access · hybridAbstract read
In one paragraph

Article in Biochemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Atypical RhoUV GTPases in development and disease.Biochemical Society transactions · 2024
    Review
  4. Article
  5. Review
  6. RhoGDI1 regulates cell-cell junctions in polarized epithelial cells.Frontiers in cell and developmental biology · 2024
    Article
  7. Review
  8. The Dual Function of RhoGDI2 in Immunity and Cancer.International journal of molecular sciences · 2023
    Review
  9. Review
  10. RhoG's Role in T Cell Activation and Function.Frontiers in immunology · 2022
    Review
  11. Review
  12. Review
  13. Electrostatic Forces Mediate the Specificity of RHO GTPase-GDI Interactions.International journal of molecular sciences · 2021
    Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ana Masara Binti Ahmad MokhtarDepartment of Biochemistry, University of Cambridge, 80 Tennis Court Road, Cambridge CB2 1GA, United Kingdom.
Samrein B M AhmedDepartment of Biochemistry, University of Cambridge, 80 Tennis Court Road, Cambridge CB2 1GA, United Kingdom.
Nicola J DarlingDepartment of Biochemistry, University of Cambridge, 80 Tennis Court Road, Cambridge CB2 1GA, United Kingdom.
Matthew HarrisDepartment of Biochemistry, University of Cambridge, 80 Tennis Court Road, Cambridge CB2 1GA, United Kingdom.
Helen R MottDepartment of Biochemistry, University of Cambridge, 80 Tennis Court Road, Cambridge CB2 1GA, United Kingdom.ORCID 0000-0002-7890-7097
Darerca OwenDepartment of Biochemistry, University of Cambridge, 80 Tennis Court Road, Cambridge CB2 1GA, United Kingdom.ORCID 0000-0003-0978-5425
University of Cambridge · GB

Funding

Biotechnology and Biological Sciences Research Council BB/JO1454/1Medical Research Council G0700057Medical Research Council MR/J007803/1
6 · The paper itself

Abstract

There are three RhoGDIs in mammalian cells, which were initially defined as negative regulators of Rho family small GTPases. However, it is now accepted that RhoGDIs not only maintain small GTPases in their inactive GDP-bound form but also act as chaperones for small GTPases, targeting them to specific intracellular membranes and protecting them from degradation. Studies to date with RhoGDIs have usually focused on the interactions between the "typical" or "classical" small GTPases, such as the Rho, Rac, and Cdc42 subfamily members, and either the widely expressed RhoGDI-1 or the hematopoietic-specific RhoGDI-2. Less is known about the third member of the family, RhoGDI-3 and its interacting partners. RhoGDI-3 has a unique N-terminal extension and is found to localize in both the cytoplasm and the Golgi. RhoGDI-3 has been shown to target RhoB and RhoG to endomembranes. In order to facilitate a more thorough understanding of RhoGDI function, we undertook a systematic study to determine all possible Rho family small GTPases that interact with the RhoGDIs. RhoGDI-1 and RhoGDI-2 were found to have relatively restricted activity, mainly binding members of the Rho and Rac subfamilies. RhoGDI-3 displayed wider specificity, interacting with the members of Rho, Rac, and Cdc42 subfamilies but also forming complexes with "atypical" small Rho GTPases such as Wrch2/RhoV, Rnd2, Miro2, and RhoH. Levels of RhoA, RhoB, RhoC, Rac1, RhoH, and Wrch2/RhoV bound to GTP were found to decrease following coexpression with RhoGDI-3, confirming its role as a negative regulator of these small Rho GTPases.

Indexed as

Amino Acid SequenceCell MembraneGTP-Binding ProteinsGuanine Nucleotide Dissociation InhibitorsHEK293 CellsHumansMonomeric GTP-Binding ProteinsProtein Bindingrho GTP-Binding Proteinsrho Guanine Nucleotide Dissociation Inhibitor alpharho Guanine Nucleotide Dissociation Inhibitor betarho Guanine Nucleotide Dissociation Inhibitor gammarho-Specific Guanine Nucleotide Dissociation InhibitorsGTP-Binding ProteinsGuanine Nucleotide Dissociation InhibitorsMonomeric GTP-Binding Proteinsrho GTP-Binding Proteinsrho Guanine Nucleotide Dissociation Inhibitor alpharho Guanine Nucleotide Dissociation Inhibitor betarho Guanine Nucleotide Dissociation Inhibitor gammarho-Specific Guanine Nucleotide Dissociation Inhibitors

Identifiers

PMID33913706
PMCPMC8253491
OpenAlexW3158443641

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.